Tilray po akvizici BrewDog zvýšil tržby z alkoholu na 101,5 mil. USD, čímž překonal 56,1 mil. USD z konopí, a v 1. čtvrtletí fiskálního roku 2027 dosáhl rekordních tržeb.
Tilray (TLRY -4.10%) isn't just a pot company anymore. In fact, you might argue that it is more of a beer company than a marijuana company at this point. And that could be exceptionally good news for investors, since the company is now more diversified. Here's why Tilray has chosen to go down this path, the key milestone it just achieved, and why it points to a brighter long-term future.
Wall Street loves a good story When Tilray went public, marijuana was all the rage. Pot was increasingly being legalized, and investors believed it would be a huge growth opportunity. Tilray's stock rocketed higher. But it wasn't the only company trying to capitalize on the dynamics in the marijuana sector. A large number of companies jumped in, creating intense competition.
Image source: Getty Images.
And then there was the old competition, illegal sellers, that didn't go away. It turned out to be harder than expected to turn a profit in the marijuana sector. When investors realized that fact, they dumped pot stocks, including Tilray. Today, Tilray's stock price is roughly 99% below its all-time high set shortly after its initial public offering. That said, it has managed to survive and adapt.
Tilray goes down a different road At this point, it is clear that marijuana demand will grow over time. So it isn't a bad business to be in. However, it is also clear that the opportunity isn't as exciting as it seemed at first. This is why Tilray began investing in alcoholic beverages, positioning itself as "a global lifestyle and consumer packaged goods company." Its focus is now spread across beverages, marijuana, and wellness. (Wellness basically means CBD-related products.)
In fiscal 2026, the company made an important acquisition, buying beverage company BrewDog. That has transformed the portfolio, with alcoholic beverages generating $101.5 million in revenue in the first quarter of fiscal 2027, up from $55.7 million in the same quarter of 2026. Marijuana revenues came in at $56.1 million, down from $64.5 million in the first quarter of fiscal 2026. Tilray is an entirely different business today than it was a year ago.
While there is still opportunity for growth in the marijuana sector, the core of the company's business is its beverage operations. That's a far more developed industry and one that is likely to be fairly predictable. In other words, Tilray has created a stronger foundation from which to grow. As an investor, you should probably see that as a very positive shift.
TLRY Tilray Brands$2.81-$0.12 (-4.10%)
NASDAQ · As of 4:00 PM ET 10/23/26
Tilray still has a lot of work to do The growth of the beverage business wasn't the only positive from the fiscal first quarter of 2027. Tilray also reported record revenues and improved its gross margin by three percentage points. Moreover, it reduced debt in the quarter, ending the period with a net cash position (meaning it had more cash than debt on its balance sheet).
There's just one not-so-small problem: Tilray is still bleeding red ink. So while progress is being made from a business perspective, from a profit perspective, the company remains a big investment risk. Clearly, Tilray's long-term goal is to be a sustainable and profitable business. The beverage shift is part of the process of achieving that goal, but only more aggressive growth investors are likely to find the stock interesting at this point.
But even more conservative investors may want to keep Tilray on the watch list. If it does manage to become sustainably profitable, it could be an interesting way to add marijuana exposure to your portfolio without jumping into the still-developing pot sector with both feet.
Portugalský regulátor INFARMED schválil společnosti Tilray Medical provádění interních mikrobiologických a fyzikálně-chemických testů ve výrobním závodě v Cantanhede s certifikací EU-GMP, což má urychlit uvolňování produktů.
CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing, and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.
Rajnish Ohri, President, International, Tilray Brands, stated: “As regulated medical cannabis markets continue to mature, the companies best positioned to lead will be those that combine pharmaceutical-grade quality, regulatory discipline, and reliable global supply at scale. Tilray has built one of the world’s leading EU-GMP-certified medical cannabis operations, and this approval further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production. It gives us greater speed, control, and flexibility across our international supply chain while reinforcing the infrastructure and technical expertise required to serve patients, physicians, pharmacies, and commercial partners with trusted medical cannabis products in high-standard markets around the world.”
For Tilray Medical, bringing critical quality testing in-house creates an important operational advantage in the fast-evolving global medical cannabis market. By reducing reliance on third-party testing for flower lots, the Company can lower batch-release costs, shorten testing timelines, and move product more efficiently from harvest to release and sale. These capabilities strengthen Tilray Medical’s ability to manage supply across key international markets, including Germany, the United Kingdom, Poland, Italy, and other regulated medical cannabis markets, while supporting more reliable access for patients and commercial partners.
This milestone builds on Tilray Medical’s broader international momentum, including increased output at its EU-GMP-certified Portugal facility and the expansion of Tilray Medical-branded cannabis medicines in the United Kingdom through Lyphe Clinic and Lyphe Dispensary. Together, these initiatives strengthen Tilray Medical’s position as a trusted global medical cannabis supplier with the infrastructure, regulatory expertise, and commercial reach to compete in high-standard pharmaceutical markets.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is a global leader in medical cannabis, having served patients in more than 20 countries across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements in this communication include statements regarding the expected benefits of the INFARMED approval, including reduced batch-release costs, shortened testing timelines, accelerated product release supply to international markets, and our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Společnost Tilray ve fiskálním prvním čtvrtletí spálila 16,5 mil. USD v hotovosti oproti 1,3 mil. USD před rokem, zatímco tržby z konopí meziročně klesly o 13 % na 56,1 mil. USD.
Last week, Tilray Brands (TLRY -5.08%) reported its first-quarter numbers for fiscal 2027. While management boasted of its record-breaking numbers and diversified business, investors shouldn't buy the hype at all.
Tilray has been a bad investment for many years, and acquisitions may have boosted its revenue, but they haven't changed the story around this troubling marijuana stock. It's a bad buy, and the three numbers below from its earnings report only confirm that.
Image source: Getty Images.
Tilray's cash burn spiked to more than $16.5 millionI've written about cannabis stocks for years and know how unreliable looking at their income statements can be; they're often filled with impairment charges and valuation changes. There's a lot of noise that can make it difficult for investors to truly understand what shape the business is in. This is why I often go straight to the cash flow statement instead.
And on a cash basis, things don't look good for Tilray. Its cash burn for the period ending Aug. 31 totaled $16.5 million, which is up significantly from $1.3 million a year ago. Cash can fluctuate significantly from one period to the next. But the reality is that Tilray has often struggled to generate consistent positive cash flow from its operations. This is even before factoring in any money it uses up from investing activities, including capital expenditures.
Tilray is a cash-burning machine, and until that changes, investors should brace for and expect stock offerings, dilution, and plenty of volatility.
Its cannabis revenue fell by 13%Tilray's cannabis revenue for the period totaled $56.1 million, which was down from $64.5 million a year ago, representing a year-over-year decline of 13%. The company's top line did rise by 23%, but that was largely due to a significant spike in its beverage business, where its BrewDog acquisition padded its numbers.
Wheeling and dealing can help manufacture this type of growth, but it's organic growth that growth investors are truly craving. Simply adding more companies to the mix can certainly make the business bigger, but not necessarily better.
Investors should tread carefully with acquisition-hungry businesses such as Tilray for this very reason, because without a way to gauge how well it's growing organically, it's difficult to see just how strong a growth stock it really is.
The fact that its core cannabis business is struggling highlights precisely why Tilray would seek investments and acquisitions elsewhere: without them, its top line wouldn't look nearly as strong.
Operating expenses soared to $101.6 millionAcquisitions can bolster the top line, but they can also drastically weigh down the bottom line. That's because a company acquires the extra staff, overhead, and other costs associated with the business. So while it may get a bump up on the top line from more revenue, it will also incur significantly more expenses. It may be able to trim some costs and remove redundancies over time, but the business will no doubt be bulkier.
Tilray's operating expenses totaled $101.6 million this past quarter, which is an increase of 83% from the same period last year. That is, however, with the company getting a $15 million benefit from the change in the fair value of contingent consideration a year ago. If that's removed, then the year-over-year increase in operating expense is 44%. But that's still higher than the company's top-line growth.
With a more bloated business, Tilray's actually going in the opposite direction of its peers, Canopy Growth and Aurora Cannabis, which have been looking to get leaner. It's not a strategy I think will end up paying off for Tilray.
Premium Feature
Moneyball Superscore
38/100
Today's Change
(
-5.08
%) $
-0.18
Current Price
$
3.36
Tilray's decline isn't likely to end anytime soonDespite top-line growth, the market didn't appear impressed with Tilray's latest numbers, as the stock has fallen since it posted them. Unfortunately, I don't see a path for the stock to get out of its tailspin anytime soon. It's a stock that's full of risk and that investors are likely better off avoiding.
Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis ConsolidationTilray Brands NASDAQ: TLRY reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Net revenue rose 23% year over year to $257.1 million, while gross profit increased 35% to $77.5 million. Consolidated gross margin expanded by about 300 basis points to 30%, CFO Carl Merton said during the company’s earnings call.
Get Tilray Brands alerts:
The Cannabis Sector's Billion-Dollar Tax CutThe company reported a net loss of $40 million, compared with net income of $1.5 million in the prior-year quarter. Tilray said its adjusted net loss, excluding non-cash and non-recurring items, was $3 million, including roughly $5 million of net cash interest expense. Adjusted EBITDA was $9.2 million, down from $10.2 million a year earlier.
International cannabis grows as total cannabis revenue declines International cannabis revenue increased 21% to $16.2 million, supported by patient demand in Germany and contributions from U.K.-based patient access business Lyphe. Tilray said EMEA revenue, including medical cannabis, beverage and pharmaceutical distribution, rose more than 70% during the quarter.
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsTotal cannabis revenue, however, declined to $56.1 million from $64.5 million a year earlier. Merton said the company prioritized profitable international opportunities over lower-return volume. Tilray also redirected approximately one metric ton of inventory, representing $1.1 million of potential Canadian revenue, to international markets.
Cannabis gross margin rose to 39% from 36%, aided by operating efficiencies, product mix improvements in Canada and greater use of the company’s Portugal facility. Those gains partly offset $8.8 million in international cannabis price compression, according to Merton.
Management said its Portugal cultivation operation has reduced operating and cultivation costs by about 40% while improving strains and potency. Tilray expects the facility to produce more than 40 metric tons of flower at full capacity during fiscal 2027. Its Aphria RX operation in Germany is operating at full capacity, the company said.
Tilray said its CC Pharma distribution business offers access to more than 16,000 pharmacies and serves as a connector between pharmaceutical distribution, medical cannabis and patient access in Europe. Distribution revenue rose 14% to $84.3 million, while segment gross margin remained 11%.
BrewDog lifts beverage revenue and margins Beverage revenue increased 82% year over year to $101.5 million, including $55.9 million of incremental revenue from BrewDog. Beverage gross margin expanded by approximately 300 basis points to 41%.
Management said BrewDog became profitable in the first quarter after Tilray stabilized operations, reduced costs, renegotiated or avoided certain leases and moved away from unprofitable activities. The company also cited a favorable summer period for its retained bars and pubs, along with improving brand sales following new marketing campaigns.
“The budget for this year is profitability and some good profitability coming from BrewDog,” management said in response to an analyst question.
Tilray said BrewDog’s Punk IPA sales at its top six off-trade retailers were up 187% over the prior-year period in the two weeks following the rollout of its latest campaigns. BrewDog also added more than 9,000 distribution points for a new craft beer product and signed eight on-trade partnerships across entertainment, sports, pubs and hotels, according to the company.
In the U.S., Tilray said it continues to rationalize beer brands and SKUs, consolidate brewery operations and focus on priority channels, retailers and distributors. Management said the legacy U.S. craft beverage business would have posted a revenue decline excluding BrewDog because of those rationalization efforts.
The company cited Circana data for the 14 weeks ended Aug. 30 showing Tilray was the No. 2 craft vendor in Georgia and the West and No. 4 in New York state. It said SweetWater represented 12% of craft beer sales in Georgia.
Tilray also highlighted its multiyear agreement with Carlsberg Group. Beginning Jan. 1, 2027, Tilray expects to produce, market, sell and distribute Carlsberg Elephant 1664 and Kronenbourg 1664 Blanc throughout the United States. Management described the arrangement as a profit-sharing venture and said all Carlsberg products covered by the agreement would be produced in Tilray’s U.S. facilities.
Balance sheet and outlook Tilray ended the quarter with approximately $221 million in cash, restricted cash and marketable securities. The company retired $24 million of principal during the quarter and another $12 million after the quarter ended, leaving $52 million outstanding, Merton said.
The company raised a modest amount through its at-the-market program and had $70 million of remaining availability. Merton said BrewDog did not require cash injections during the quarter and was self-financing after an initial funding period tied to its payment cycle.
Wellness revenue was relatively stable at $15.3 million. Merton said segment margin pressure reflected a one-time shortage of organic hemp seed that affected the company’s e-commerce product mix.
Looking ahead, management said it expects fiscal-year results to be more heavily weighted toward the second half because of seasonality across beverage, cannabis and distribution. The company said its priorities include expanding cannabis margins through cultivation efficiencies and international scale, integrating BrewDog, optimizing its beverage manufacturing footprint, preparing for the Carlsberg transition and reducing debt and interest costs.
“Market conditions remain mixed across several categories,” Merton said, but he added that Tilray remains focused on “disciplined execution, profitable growth, and building a stronger global platform.”
About Tilray Brands (NASDAQ:TLRY)Tilray Brands, Inc is a global consumer packaged goods company focused on cannabis, beverage alcohol, wellness and consumer products. The company develops, produces, distributes and markets a range of cannabis products, including dried flower, pre-rolls, vapes, edibles and medical cannabis products, subject to applicable regulations in the markets it serves.
Tilray also operates beverage alcohol businesses, including craft beer, spirits and other alcoholic beverages. Its portfolio has included brands such as SweetWater Brewing Company, Montauk Brewing Company and Breckenridge Distillery.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Tilray Brands Right Now?Before you consider Tilray Brands, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray Brands wasn't on the list.
While Tilray Brands currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
BrewDog uvádí, že prodeje Punk IPA a Hazy Jane u šesti hlavních maloobchodních partnerů meziročně vzrostly na 2,87násobek ve srovnatelném dvoutýdenním období.
Bold UK-wide campaign puts craft beer back at the centre of culture, celebrating better ingredients, better quality, skilled brewers, beer lovers and the big flavours that make craft worth choosing.
BrewDog consumers are back: sales across the brand’s top six off-trade retailers are up 2.87 times for Punk IPA vs last year’s volume for the same two-week period as the Under New Ownership and Choose Craft campaigns roll out across the UK.
ELLON, Scotland, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is building commercial momentum under Tilray ownership, with a strong weekly sales snapshot and eight new on-trade partnerships spanning live entertainment, sport, pubs and hotels. Its UK-wide Choose Craft campaign will support that momentum, celebrating the quality, flavour and character that make craft beer worth choosing.
Choose Craft marks a confident new chapter for BrewDog and a rallying call for beer lovers across the UK. The campaign, by McCann Manchester, builds on the belief that quality still counts, the campaign celebrates the flavour, craft, creativity and attitude that set great beer apart, and signals BrewDog’s renewed momentum as it champions the category it helped define. The momentum is already showing at retail: since BrewDog began rolling out Choose Craft, EPOS data shows sales across its top six off-trade retailers are up 2.87 times for Punk IPA and Hazy Jane vs last year’s volume for the same two-week period as the Under New Ownership and Choose Craft campaigns roll out across the UK. Building on that momentum, new BrewDog craft beer innovation has secured more than 9,000 new distribution points across the UK. Alongside that retail momentum, BrewDog has secured eight new on-trade partnerships since Tilray took ownership, expanding its presence across live entertainment, sport, pubs and hotels. These include an Official Beer Partner agreement with Underbelly, bringing BrewDog’s full range to Edinburgh Fringe, Boulevard Soho, Skate in Leicester Square and Skate in Trafalgar Square, and a five-year Official Beer Partner agreement with Leicester Tigers. As well as some high profile on trade accounts such as Ladhar, Kew Green and Malones.
Choose Craft is rolling out now across the UK through bold, high-visibility placements, including murals in Manchester and Edinburgh, static and digital advertising across major national railway and underground stations, roadside locations and proximity advertising near key stockists. More than visibility, the campaign is designed to remind beer lovers why craft became a movement: quality ingredients, distinctive flavour, bold ideas and the details that make beer something people actively seek out, talk about and choose with pride.
For BrewDog, the message is clear: the brand is back with purpose, energy and a sharper point of view. Following its Under New Ownership campaign, BrewDog is building on the spirit that made it iconic — uncompromising beer, a passionate community and a belief that craft should lead culture, not follow it.
John Beasley, Chief Marketing Officer, comments: “Choose Craft is a campaign with conviction. It is about putting quality, flavour and the craft beer community back in the spotlight — and reminding beer lovers across the UK why great beer is worth choosing. BrewDog is back with confidence, focus and momentum. We have always believed beer should have character, flavour and attitude. As the UK’s leading craft beer brand, we have a responsibility to champion quality, celebrate the brewers and beer lovers who built this movement, and give people every reason to choose craft.”
BrewDog is giving beer lovers more ways to join in and choose craft, including a grocery and BrewDog.com promotion on 10-packs of Lost Lager for £10, a Tesco-exclusive competition inviting shoppers to help create the next BrewDog beer, and a Scratch to Win mechanic across the on-trade, with experiential activations and customer moments designed to celebrate craft beer where people discover, buy and enjoy it.
Innovation That Raises the Bar for Craft
The campaign is also backed by a fresh wave of craft innovation from BrewDog. With discovery the #2 choice driver in craft after taste, BrewDog is keeping new flavours, formats and beer experiences front and centre. Premium 440ml cans account for 27% of craft sales and attract the category’s most engaged and highest-value shoppers, who spend three times as much as the average craft consumer. BrewDog’s latest beers, alongside the recent Liquid Visions launch, build on that appetite for discovery while reinforcing the brand’s commitment to quality, creativity and choice.
First up, West Coast Session IPA, Palm Break (330ml, 4% ABV), brings bright, easy-drinking craft refreshment with a West Coast edge. Light in body yet full in character, it balances lush fruit notes with a clean snap of bitterness, leaving a refreshing, resin-kissed afterglow.
With the stout market growing at +9.1%, Hazelnut Heist (440ml, 8% ABV) leans into continued consumer interest in rich, indulgent stout styles, particularly over the winter period. A decadent chocolate vanilla stout, it is loaded with roasted hazelnut, smooth vanilla and rich cocoa.
Raspberry Ripple New England IPA, Tripple Ripple (440ml, 6% ABV), is the latest collaboration with Mackie’s Ice Cream, bringing a playful, flavour-led twist to the craft category. It follows the phenomenal performance of the first Mackie’s collab, Two Scoops Stout, which was the #1 NPD brand in the craft category in the six months post-launch and recently won Gold at the World Beer Awards.
Finally, Cloud Engine (440ml, 8% ABV) is a Double Dry Hopped New England IPA that delivers a flavour bomb of mango, passionfruit and ripe citrus, with a silky mouthfeel and none of the bitterness.
About BrewDog
BrewDog has always had one mission: making people as passionate about great beer as we are.
From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007.
Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognizable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future will continue to be shaped by the three things that matter most: People, Planet and Beer.
For more information, visit www.brewdog.com or follow @BrewDog on social media.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/537bf3f1-1e5d-4c0f-a2a7-372bd44bc76a
https://www.globenewswire.com/NewsRoom/AttachmentNg/e09104a1-231d-4281-a04b-ecc47e83d668
https://www.globenewswire.com/NewsRoom/AttachmentNg/a7acfb3e-7c16-4e3e-a72f-6b5dc40e0951
https://www.globenewswire.com/NewsRoom/AttachmentNg/05b2ee85-43f9-4f7a-a6b0-b9c131fcfec1
https://www.globenewswire.com/NewsRoom/AttachmentNg/50ae3053-9cd8-4ae5-aecb-55d019832f64
https://www.globenewswire.com/NewsRoom/AttachmentNg/48783ec8-0ee2-4c88-8a55-559a2c6dcf44
Tilray Brands vykázala ve fiskálním roce končícím 31. května rekordní čisté tržby ve výši 915 mil. USD, ale také čistou ztrátu přes 105 mil. USD a záporný peněžní tok ve výši 69 mil. USD.
Tilray Brands (TLRY +0.00%) stock has been crashing hard this year, losing close to 60% of its value thus far. On Monday, it closed at $3.72, which is an 84% decline from its 52-week high of $23.20. The stock may seem dirt cheap, but here's why even at less than $4, I still wouldn't buy it.
Image source: Getty Images.
Tilray's growth prospects simply aren't that goodAlthough Tilray's stock is down big this year, it's for good reason: the business just doesn’t look all that appealing ot invest in.
With hopes of significant marijuana reform fading in the U.S., there's been less and less of a reason for investors to be bullish on Tilray’s business. Meanwhile, the Canadian market is highly competitive, and margins are small. The company has been expanding via acquisitions, loading up on beverage brands that other companies are more than willing to get rid of because they aren't top performers. And while that's a good way to temporarily boost the company's revenue, it doesn't fundamentally put Tilray in a good position to achieve strong growth in the future.
Although the cannabis company reported record net revenue of $915 million in its most recent fiscal year, which ended on May 31, it still incurred a net loss of more than $105 million. It's also continued to be a cash-burning machine, using up $69 million during the fiscal year. Tilray has a long way to go in proving to investors that it's worth investing in.
Premium Feature
Moneyball Superscore
35/100
Today's Change
(
0.00
%) $
0.00
Current Price
$
3.72
The stock could still go lowerThere isn't a magic number that makes Tilray's stock suddenly worth buying. It has crashed by 97% over the past five years, and time after time, Tilray has burned investors who thought the stock had bottomed out, only for it to end up hitting a new low.
I don't believe the company's pivot to beverages is a good move, as it adds more complexity and pieces into the mix, for the sake of getting bigger and bolstering the top line. It's a strategy that I don't think will ultimately pay off, as I believe Tilray is just biding its time until the U.S. market opens up (assuming legalization takes place in the future, which is by no means a guarantee).
Its losses are likely to continue to drive the stock lower, and whether it's $4 or $3, or less than that, the stock will remain a highly speculative and risky buy, one that most investors are likely better off simply avoiding.
Even among marijuana stocks, Tilray Brands (TLRY -2.84%) has performed poorly year to date. Since January, the stock has fallen by nearly 56%. Over the past five years, on a split-adjusted basis, Tilray shares have fallen by over 96.7%.
This comes even as Tilray, now diversified beyond the recreational cannabis market, keeps reporting incremental improvements in operating performance. However, two issues driving Tilray's downward spiral remain unresolved.
Image source: Getty Images.
Tilray reported record results, but the stock can't stop sinking As discussed in Tilray's Q4 earnings release for its fiscal 2026, ended May 31, the company reported a record $915.5 million in revenue, up 11% from the prior fiscal year. Tilray also reported an 8% increase in gross profit, along with an 11.1% increase in adjusted EBITDA, from $55 million to $61.1 million.
However, Tilray is no longer a pure-play cannabis company. Recreational cannabis makes up less than a third of sales. Alcoholic beverages, medical marijuana distribution, and wellness products make up the remainder. Much of Tilray's operational improvement comes from its non-recreational cannabis businesses.
Moreover, while Tilray's results improved slightly, the company's ongoing share-dilution problem continues to outweigh these modest operational gains.
Premium Feature
Moneyball Superscore
34/100
Today's Change
(
-2.84
%) $
-0.12
Current Price
$
4.11
Further losses likely ahead On paper, Tilray has a lot more going for it. Management's guidance calls for Tilray's revenue to reach $1 billion this fiscal year, with adjusted EBITDA to improve further. Other strengths include Tilray's large $235 million cash position and nearly debt-free balance sheet, plus the potential from large strategic partnerships, like its upcoming agreement to license and sell Carlsberg-branded beer products in the United States.
But as more important metrics, like GAAP profitability, remain elusive and the share count continues to rise, it's difficult to see Tilray reversing course. Between Jan. 6 and July 26 of this year, Tilray's share count climbed from 116.5 million to 136.2 million. Tilray owns a lot of businesses, but has scant exposure to the U.S. recreational cannabis market.
Tilray Brands letos klesla o 55 % na 4,15 USD, ale tržby za poslední fiskální rok vzrostly o 11 % na 915 milionů USD. Firma zároveň zúžila ztrátu za čtvrtletí.
Tilray Brands stock has remained under pressure and is underperforming the market this year. TLRY was trading at $4.15 after falling by 55% since January and by 62% in the last 12 months. Still, a contrarian case can be made despite its ongoing challenges.
The cannabis industry is going through a tough situation, with demand falling, competition rising, and the rescheduling taking longer than expected.
Tilray Brands’ business has been affected by these developments. Nonetheless, a closer look at its recent results shows that its business is doing relatively well.
The most recent results shows that its annual revenue rose by 11% to $915 million in the last financial year. It rose by 25% in the fourth quarter to $281 million, partly because of its acquisitions.
Its cannabis revenue rose by 5% to $71.5 million, with its gross margin remaining unchanged at 44%. The beverage business generated $105 million in revenue, up sharply from the $65.6 million it made last year. Also, its annual revenue rose by 6% to over $254 million.
The distribution revenue rose by 15% to $85 million, while the smaller wellness revenue rose by 16% to $19.7 million. These numbers mean that the company is seeing modest growth across the board, which the management has pledged to accelerate.
The company also narrowed its losses during the quarter. It reported a non-cash loss of $37.9 million, mostly because of non-cash charges.
Analysts are optimistic that Tilray Brands' revenue will continue growing in the foreseeable future. The average estimate among analysts is that its annual revenue will rise by 22% to $1.12 billion. It will then hit $1.18 billion next year. In most cases, Tilray Brands tends to outperform its top-line numbers, meaning that its real figures will be better than expected.
Another potential catalyst is the rescheduling of cannabis. Tilray does not have cannabis operations in the US, meaning that it may enter the country once the rescheduling process ends. The company said:
“Following recent U.S. rescheduling developments, Tilray continues to evaluate multiple pathways to participation in an emerging federally compliant, science-driven medical cannabis market.”
TLRY stock chart | Source: TradingView
The daily chart shows that the TLRY stock has been in a strong sell-off since last year. It has formed a descending channel and remained below all moving average indicators.
The stock is hovering near the key support level of $3.69, which is part of a double-bottom pattern whose neckline is at $4.95. Therefore, the stock will likely retreat to the key support of $3.70 and then bounce back.
If this happens, the initial target will be at $4.95. A move above that level will point to more gains, potentially to $5. This view will remain as long as it is above the double-bottom of $3.70.
Tilray Brands ve fiskálním roce 2026 vykázala rekordní tržby 915 milionů USD, ale stále vykázala ztrátu 1,09 USD na akcii. Firma dál rozšiřuje byznys mimo marihuanu, zisk ale zatím nepřišel.
Tilray Brands (TLRY -2.90%) started out as a marijuana company. When it first came public, investors were enamored of pot stocks and the shares rose dramatically. But the marijuana story didn't live up to investors' elevated expectations, and Tilray's stock, along with the rest of the marijuana sector, plunged. Today, Tilray is taking a different approach, and it is starting to show positive results. But investors appear unwilling to give the stock the benefit of the doubt. Here's what's going on.
Is Tilray Brands trying to become a consumer staples company? The big story with Tilray Brands right now really isn't marijuana. What investors really need to pay attention to is management's efforts to add other products to the portfolio, including alcoholic beverages and CBD-infused items. Moreover, Tilray has been focusing heavily on its brands as it seeks to transition into "a global lifestyle and consumer packaged goods company leading at the nexus of the beverage, cannabis, and wellness industries."
Image source: Getty Images.
This is a major corporate overhaul, with Tilray effectively seeking to compete with consumer staples companies. It is a highly competitive industry where scale can be an important differentiator. That's an issue, since Tilray's market cap is a tiny $600 million. Distribution, marketing, research and development all involve material costs. It can be difficult to differentiate a company if its revenues are a rounding error relative to larger peers. And that's very much the case here, considering that Coca-Cola (KO +0.52%) generated $13.4 billion in sales in the second quarter of 2026.
That puts Tilray's record fiscal 2026 revenues of $915 million into perspective. Coca-Cola made over 13x that in just a single quarter. While it is true that comparing Tilray to one of the world's largest consumer-staples companies probably isn't fair, it does help to show just how small Tilray really is as a business.
Tilray is achieving solid success, but there's still more to do The next big issue is that Tilray isn't profitable. Despite record revenues, the company still lost $1.09 per share in fiscal 2026. That was a vast improvement over the $24.56-per-share loss in fiscal 2025, but a tiny, money-losing company in the middle of a business overhaul isn't the type of stock most investors should buy. Tilray is only appropriate for risk takers.
Premium Feature
Moneyball Superscore
34/100
Today's Change
(
-2.90
%) $
-0.12
Current Price
$
4.02
That said, it has done a very good job of diversifying its business beyond marijuana. At this point, it also has a significant business in the craft-brew niche, which it recently expanded through the acquisition of BrewDog. Moreover, revenues increased across all its business segments in fiscal 2026, suggesting the company is executing fairly well. Management just has to find a way to turn that success into profits.
From a big-picture perspective, Tilray's diversification effort and focus on becoming a consumer-staples brand manager are probably good choices. However, given the history of the marijuana industry and the company's ongoing losses, investors aren't willing to afford the company the benefit of the doubt as it looks to turn itself into a profitable business. That's entirely understandable.
Tilray: Record revenues aren't enough At the end of the day, Tilray needs to prove it can be a sustainably profitable business. Record revenues are moving the company in the right direction, as is its effort to diversify. However, until earnings turn positive, most investors are unlikely to buy Tilray stock. So, for now, Tilray remains a business that only the most aggressive investors should buy. But given the changes it is making, it might still be one you want to keep on your watch list, even if you aren't willing to own it right now.
Tilray Brands, Canopy Growth a Village Farms vstupují do září s lepšími výsledky: všechny tři vykazují růst tržeb a silnější mezinárodní expanzi. Tilray navíc dosáhl rekordních ročních tržeb přibližně 915,5 milionu USD.
The Cannabis Comeback? 3 Marijuana Stocks to Watch Now The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors’ radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry’s investment landscape.
Canadian Producers Positioned for Growth Still, investors should not depend entirely on regulatory changes to drive marijuana stocks higher. Instead, companies must demonstrate improving businesses and stronger financial results. Fortunately, several cannabis companies are beginning to deliver encouraging numbers. Tilray Brands recently completed a record fiscal year for revenue. Meanwhile, Canopy Growth reported double-digit revenue growth during its latest quarter. Village Farms International also delivered record cannabis revenue and international export sales. These improvements could make the sector increasingly interesting during September. Of course, marijuana stocks remain highly speculative investments. Sharp price movements can happen quickly following financial, regulatory, or political developments. Therefore, investors should carefully research each company before making investment decisions. Three cannabis stocks currently stand out as we enter September 2026. Tilray Brands (NASDAQ: TLRY), Canopy Growth (NASDAQ: CGC), and Village Farms International (NASDAQ: VFF) each offer different opportunities. More importantly, improving fundamentals could make these three marijuana stocks worth watching closely.
[Read More] 3 Marijuana Stocks To Focus On For Future Growth And Profits
3 Top Marijuana Stocks to Watch in September 2026 Tilray Brands (NASDAQ: TLRY) Canopy Growth Corporation (NASDAQ: CGC) Village Farms International (NASDAQ: VFF) Tilray Brands (NASDAQ: TLRY) Tilray Brands remains one of the most recognizable cannabis companies trading on a major U.S. exchange. However, the company has evolved considerably beyond its original marijuana business. Today, Tilray operates across cannabis, beverages, wellness, distribution, and hospitality. Cannabis still remains an important part of the company’s long-term strategy. Tilray owns several established cannabis brands, including Good Supply, Redecan, Broken Coast, and RIFF. Additionally, the company has developed a sizable international medical cannabis operation. Europe remains especially important to Tilray’s expansion strategy. The company has production capabilities that help serve growing international medical cannabis markets. Meanwhile, Tilray’s largest physical presence in the United States comes through its beverage and consumer businesses. Those operations include SweetWater Brewing and several additional beverage brands. However, Tilray currently operates zero marijuana dispensaries in the United States. Therefore, TLRY offers investors a different approach compared with traditional American multi-state cannabis operators.
Financially, fiscal 2026 represented an important growth year for Tilray. The company reported record annual net revenue of approximately $915.5 million. That represented an 11% increase from $821.3 million during the previous year. Cannabis net revenue also increased 8% to approximately $268.3 million. Cannabis gross profit also increased 8% to approximately $107.1 million. Meanwhile, cannabis’s gross margin remained approximately 40%. Tilray’s beverage business generated approximately $254 million in annual net revenue. Distribution revenue performed even better, reaching approximately $327.2 million. Overall gross profit increased 8% to approximately $260.4 million. Additionally, adjusted net income increased almost 90% to approximately $12.2 million. Adjusted EBITDA reached approximately $61.1 million, compared with $55 million previously. Nevertheless, Tilray reported a GAAP net loss of approximately $105.2 million. Therefore, investors should continue monitoring profitability. Still, rising revenue makes TLRY an interesting marijuana stock entering September.
[Read More] The Best Way Marijuana Stock Investing Can Work For You
Canopy Growth Corporation (NASDAQ: CGC) Canopy Growth remains another well-known Canadian cannabis company among marijuana stock investors. The company sells medical and recreational cannabis products through several established brands. Those brands include Tweed, 7ACRES, DOJA, and other recognizable cannabis names. Canada remains the company’s primary cannabis market. However, management continues pursuing growth opportunities internationally. Canopy has also maintained exposure to the potential long-term development of the American cannabis industry. Its U.S. strategy has historically involved Canopy USA and several recognizable cannabis businesses. However, investors should distinguish Canopy Growth’s operations from separately structured American cannabis interests.
Meanwhile, Canopy’s international cannabis operations could become increasingly important. Europe provides another opportunity as medical marijuana markets continue developing. Additionally, Canopy Growth has strengthened its Canadian cannabis portfolio through acquisitions. The company does not directly operate a traditional nationwide U.S. marijuana dispensary network. Therefore, its current investment story depends heavily on improving Canadian operations, expanding internationally, and delivering stronger financial performance.
Canopy Growth’s latest financial results provided several encouraging signs entering September. First-quarter fiscal 2027 net revenue reached approximately C$81.2 million. That represented 13% year-over-year growth. Cannabis net revenue increased 14% to approximately C$65.1 million. Moreover, Canadian adult-use cannabis revenue increased 10% to C$29.7 million. Canadian medical cannabis performed even better during the quarter. Medical cannabis revenue increased 22% to approximately C$25.8 million. Additionally, international cannabis revenue increased 10% to C$9.6 million. Strength in Europe, particularly Poland, helped support international growth. Meanwhile, adjusted gross margin improved to 31%, compared with 25% previously. Most importantly, Canopy continued reducing its losses. The company’s net loss narrowed to approximately C$14.6 million during the quarter. That represented a 68% year-over-year reduction. Therefore, Canopy appears to be moving toward stronger financial performance. Consequently, CGC remains a marijuana stock worth monitoring closely throughout September 2026.
[Read More] 3 Marijuana Stocks To Watch At The End Of The Week
Village Farms International (NASDAQ: VFF) Village Farms International offers investors a different approach to the cannabis industry. The company developed its expertise through decades of controlled-environment agriculture and large-scale greenhouse production. Today, cannabis has become the company’s primary growth engine. Village Farms owns Pure Sunfarms, one of Canada’s leading cannabis producers. Pure Sunfarms operates large greenhouse facilities in British Columbia. Additionally, Village Farms owns a controlling interest in Quebec-based cannabis company Rose LifeScience.
The company has also expanded aggressively into international medical cannabis markets. Europe has become particularly important to its long-term growth strategy. Meanwhile, Village Farms continues developing its cannabis operations in the Netherlands. These international businesses could provide additional growth opportunities over the coming years. In the United States, Village Farms has exposure through its hemp-derived cannabinoid business. However, the company currently operates zero marijuana dispensaries in the United States. Therefore, VFF’s cannabis growth story currently centers heavily around Canada, Europe, and international exports.
Financially, Village Farms delivered impressive second-quarter 2026 results entering September. Consolidated net sales reached approximately $64 million. That represented 7% year-over-year growth and 27% sequential growth. More importantly, cannabis net sales reached a record $53.5 million. Cannabis gross margin also improved significantly to 51%. The comparable margin during the previous year was approximately 42%. Additionally, cannabis net income increased 21% to approximately $8.6 million. Adjusted cannabis EBITDA reached a record $15.3 million. That represented approximately 29% of cannabis sales. International exports were another major bright spot. Export sales reached a record $20.9 million. That represented 74% year-over-year growth and 43% sequential growth. Furthermore, consolidated net income reached approximately $7.1 million, or $0.06 per share. Operating cash flow totaled approximately $8.9 million. Village Farms also ended the quarter with approximately $73 million in cash. Therefore, VFF could be one of the more interesting marijuana stocks to watch during September 2026.
Tilray oznámila rekordní tržby za poslední fiskální rok ve výši zhruba 915 milionů USD, ale podle GAAP vykázala ztrátu 49,6 milionu USD. Investory dál brzdí i to, že konopí tvoří jen 29 % tržeb.
Late last month, Tilray Brands (TLRY +3.64%) released its latest fiscal results and guidance updates. The market reacted positively to both, resulting in a modest post-earnings rally.
Since then, however, the bull run for one of the most-followed marijuana stocks has run its course. This is especially interesting, given that the U.S. legalization catalyst seems to be strengthening at the same time. Still, considering several factors, it is not surprising that investors appear hesitant to bid up Tilray shares.
Image source: Getty Images.
Tilray's earnings were not much of a game changer Take a look at Tilray's latest quarterly financials, released on July 28, and you'd think that the Canada-based cannabis company had turned a corner. In the earnings release, management touted the company's "record revenue and adjusted EBITDA" and provided promising guidance for the coming fiscal year.
Today's Change
(
3.64
%) $
0.17
Current Price
$
4.84
Yes, last fiscal year, revenue increased by 11%, to around $915 million, signaling that Tilray's getting close to hitting its $1 billion annual revenue target. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 11%, to $61.1 million. Adjusted net income, rising from $6.5 million to $12.2 million, nearly doubled as well. Even so, adjusted earnings fell short of sell-side forecasts. Worse yet, on a GAAP basis, Tilray once again reported heavy losses, with net losses attributable to Tilray shareholders totaling $49.6 million, or negative 43 cents per share.
Other factors keep investors hesitant about the stock For fiscal year 2027, Tilray's management expects adjusted EBITDA of $68 million to $75 million, yet it's unclear whether this will translate into a swing to positive GAAP earnings. Management may also be touting how it's cut Tilray's debt to effectively zero, but it's doing so in a dilutive manner: through debt-for-equity swaps.
Even as the U.S. federal government's marijuana rescheduling efforts continue, Tilray has relatively limited exposure to this catalyst. Now diversified into areas such as alcoholic beverages and pharmaceutical distribution, cannabis accounts for just 29% of overall sales. Barring an end to share dilution, a significant improvement in results next quarter, or a big pivot back toward recreational cannabis, ho-hum price action will likely persist.
Tilray zvýšila roční pěstební kapacitu konopí na zhruba 275 metrických tun z 210, aby uspokojila rostoucí mezinárodní poptávku po léčebném konopí. Růst táhne hlavně Quebec a Portugalsko.
NEW YORK and TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company at the forefront of the cannabis, beverage, hospitality and wellness industries, today announced a major expansion of its global cannabis cultivation capacity to meet accelerating international medical cannabis demand. Across its worldwide operations, Tilray has increased annual cultivation capacity to approximately 275 metric tonnes, up from 210 metric tonnes, driven by expanded output at its Quebec facility in Canada and its EU-GMP-certified facility in Portugal.
Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: “Tilray is defining what global leadership in cannabis looks like. We are expanding production across Canada and Europe, increasing global capacity to approximately 275 metric tonnes, and strengthening the supply infrastructure needed to serve patients and partners across the world’s most important medical cannabis markets. As demand accelerates, Tilray is leading with scale, discipline and a differentiated international platform built for long-term growth.”
Tilray has increased annual cultivation capacity at its Quebec facility by 30 metric tonnes, materially increasing inventory for the Quebec market while adding supply for Europe, Australia and other regulated international markets. The Quebec facility is also on track to achieve EU-GMP certification within the next 12 months, further strengthening Tilray’s ability to produce medical cannabis to globally recognized quality standards. Tilray is now shipping Quebec-grown bulk cannabis directly to its sites in Portugal and Australia. The Company has also increased output at its EU-GMP-certified Portugal facility, one of Europe’s largest medical cannabis production sites and the anchor of Tilray’s European supply chain, strengthening supply to Germany, the United Kingdom and other European markets. In Germany, Tilray has also strengthened its cultivation operations, with its Aphria RX facility fully utilized and its new ARX brand launched successfully with strong early patient response.
The expansion of Tilray’s international cannabis operations further strengthens its position as a global cannabis leader. As an industry pioneer, Tilray continues to lead with a differentiated global platform that connects scaled cultivation, pharmaceutical distribution and vertically integrated patient-access platforms, including HelloMD in Canada and Lyphe Clinic in the United Kingdom, to expand access across the world’s most important medical cannabis growth markets.
As medical cannabis markets continue to mature, Tilray is building the trusted international infrastructure required to lead regulated cannabis at scale—expanding patient access, supporting healthcare providers and government partners, and setting the standard for responsible global growth.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX and Broken Coast. Tilray grew from one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments in 20 countries.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America. Tilray is building a transformative platform at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in more than 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward looking statements in this communication include, but are not limited to, statements regarding expected increases in global and site-level cultivation capacity, including anticipated annual capacity of approximately 260 to 275 metric tonnes and expanded output at the Company’s Quebec and Portugal facilities; the expected timing of EU-GMP certification at the Quebec facility and the Company’s plans to launch products to EU-GMP standards; expectations regarding bulk shipments from Quebec to the Company’s facilities in Portugal and Australia; the availability of inventory to support international markets; the integration and expansion of the Company’s UK platform following the acquisition of Lyphe Group; and the Company’s position and growth prospects within the international cannabis industry. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Tilray Medical spustila ve Velké Británii přímý prodej svých konopných květových produktů značky Tilray Medical prostřednictvím Lyphe Clinic a Lyphe Dispensary. Firma tím rozšiřuje dostupnost pro pacienty a podporuje růst své britské platformy.
LONDON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced the UK launch of Tilray Medical-branded cannabis flower products through Lyphe Clinic and Lyphe Dispensary, creating a direct-to-patient channel that broadens access for patients across the country and supports the continued commercial growth of Tilray Medical-branded cannabis medicines in the UK.
The launch marks an important milestone in Tilray’s integration of Lyphe Group and demonstrates the Company’s differentiated medical cannabis platform in the UK, bringing together European cultivation, pharmaceutical manufacturing, clinical care, prescribing, dispensing and patient support within a connected healthcare model.
Rajnish Ohri, President, International, Tilray Brands, stated: “This launch is a defining step in Tilray Medical’s UK strategy and a powerful example of how we are building a more connected, patient-centered medical cannabis platform. By bringing Tilray Medical-branded cannabis medicines to patients through Lyphe Clinic and Lyphe Dispensary, we are combining high-quality European cultivation and pharmaceutical manufacturing with trusted clinical, prescribing, dispensing and patient care services. This integrated model strengthens responsible access for patients, supports healthcare practitioners and reinforces Tilray Medical’s commercial leadership in regulated medical cannabis markets.”
Tilray Brands acquired Lyphe Group in April 2026, establishing a differentiated UK medical cannabis platform spanning clinical care, prescribing, dispensing and pharmaceutical distribution. The addition of Tilray Medical products to Lyphe Clinic and Lyphe Dispensary strengthens this model by connecting Tilray Medical’s global production network with Lyphe’s established patient and pharmacy infrastructure.
The rollout reflects Tilray Medical’s commitment to responsible access across regulated international medical cannabis markets and leverages the scale, quality standards and supply-chain capabilities of its global operations. The range available through Lyphe Clinic and Lyphe Dispensary is expected to expand over the coming months, with Tilray Medical products cultivated and produced through the Company’s international production network, including its EU-GMP-certified facility in Portugal.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX and Broken Coast. Tilray grew from one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments in 20 countries across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America. Tilray is building a transformative platform at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in more than 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward looking statements in this communication include, but are not limited to, statements regarding the integration of Lyphe Group into Tilray Medical's operations; the anticipated benefits of such integration; the expansion, development and commercialization of Tilray Medical's UK platform; expectations regarding future product availability and commercialization opportunities; the Company's ability to support patient access in regulated markets; and the Company's position and growth prospects within the international medical cannabis industry. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Akcie Tilray Brands vzrostly téměř o 4 % po zprávě, že Curaleaf chystá nepřátelskou nabídku na převzetí Aurora Cannabis. Akcie Aurora na zprávu přidaly 20 %.
Tilray Brands stock rose by nearly 4% as investors rotated to companies in the cannabis industry after a report said that Curaleaf was planning a hostile bid for Aurora Cannabis. TLRY rose to an intraday high of 4.70, up by 25% from its lowest level this year.
According to the WSJ, Curaleaf, which is valued at $2.2 billion, plans to launch a hostile bid for Aurora, a Canadian cannabis company, after its board refused to negotiate. Curaleaf stock jumped by 2.35%, while Aurora rose by 20% to $3.45, valuing it at $226 million. Aurora plans to buy it in a $272 million deal.
Other cannabis companies jumped, with the AdvisorShares Pure US Cannabis ETF (MSOS) rose by over 2%. In a statement, the Chief Executive of Curaleaf said:
“We will now take our proposal directly to Aurora shareholders because the premium is significant, the strategic rationale is compelling, and further delay is unjustified.”
Tilray Brands, valued at over $624 million, jumped after the M&A report sparked excitement across the industry. Some investors believe the company could also become a takeover target if the sector enters a consolidation phase.
The M&A news came at a time when the cannabis industry is waiting for a major deadline in the reclassification process in the US. On August 17, participants in the DEA rescheduling hearing will submit their post-hearing briefs to the administrative law judge (ALJ) by this date.
After this, the ALJ will submit a report with recommendations, a process that may take weeks or months, with participants given 20 days to file formal objections.
Tilray Brands, which was once one of the biggest cannabis companies, has gone through some major changes. It has expanded its business to other countries like Germany, the Netherlands, and in Latin America. This division grew by 36% in the second quarter of the year.
The company has also expanded aggressively in the beverage industry, making major acquisitions, including companies like BrewDog and brands from companies like Molson Coors and AB InBev.
Its most recent results showed that Tilray’s revenue rose by 11% in the last financial year to $915 million. Its cannabis, beverage, distribution, and wellness revenues rose to $268 million, $254 million, $327 million, and $65 million, respectively.
Tilray Brands očekává, že v příštím fiskálním roce překročí čisté tržby 1 miliardu USD. V minulém fiskálním roce dosáhla čistých tržeb 915,5 milionu USD, což představuje meziroční nárůst o 11 %.
Tilray Brands (TLRY -2.95%) recently posted record earnings numbers and is focused on even more growth ahead. For the coming fiscal year, it anticipates full-year revenue will exceed $1 billion. It would be a huge milestone for the company, whose growth prospects have been a big concern in recent years.
For growth investors, it may seem a bit surprising, given that marijuana legalization still isn't on the horizon in the U.S., making it challenging for Tilray to continue finding ways to grow. But here's how it believes it can get to $1 billion in revenue.
Image source: Getty Images.
How Tilray expects to hit new records for fiscal 2027 Last month, Tilray wrapped up its 2026 fiscal year (which ended on May 31) with net revenue totaling $915.5 million, up 11% from a year ago, when its top line totaled $821.3 million. That's a solid growth rate, particularly at a time when many businesses are struggling to grow due to economic challenges, including higher prices.
Tilray, however, has been leveraging opportunities in international markets as well as through acquisitions in its beverage segment to unlock more growth. And those are the areas that it's continually focusing on in the coming year. CEO Irwin Simon says that the business has entered the fiscal year "a stronger company than ever before, " highlighting Tilray's strong medical and cannabis business in Europe and its growing craft beer portfolio.
While reaching $1 billion in sales would be impressive, the cannabis company could achieve that milestone even if its growth rate slowed; its top line would need to increase by just over 9% to hit that target. Thus, it's a milestone that may be highly attainable, particularly if Tilray continues to expand internationally and adds to its craft beer portfolio through acquisitions.
Today's Change
(
-2.95
%) $
-0.14
Current Price
$
4.44
Why more growth may not be enough to turn Tilray's stock around Tilray has been growing its business over the years, and while getting to $1 billion may be a huge milestone, the market may be looking for much more: profitability. This past fiscal year, it incurred a loss of more than $105 million. While that was an improvement over a year ago, when it was more than $2 billion due to significant impairment charges, the business still hasn't demonstrated it can be consistently profitable.
Continual cash burn and costly acquisitions have weighed on the stock for years -- it's down 97% in five years -- and it may continue to struggle until it can prove to investors that it can grow and stay out of the red. Although it's growing, Tilray is still a risky stock to own.
Tilray Brands vykázala za fiskální rok končící 31. května tržby 915,5 milionu USD, o 11 % více, a největší růst táhl distribuční segment. Jeho tržby přesáhly 327 milionů USD a stouply o 21 %.
Tilray Brands (TLRY +4.51%) has become much more diverse in recent years. It's become more than just a cannabis producer, as acquisitions in beverages have significantly broadened its opportunities and grown its operations. It's also been expanding into international markets.
Last week, the company reported its year-end numbers for fiscal 2026, and what was surprising was where the bulk of its revenue growth came from. It wasn't from beverages or even from the Canadian cannabis market. Instead, its distribution business was responsible for the vast majority of its growth.
Image source: Getty Images.
Tilray's distribution business grew by 21% last year Tilray has four main segments, including beverages, cannabis, distribution, and wellness. It's largely known for being a cannabis producer, and it's been becoming a bigger player in the beverage industry due to acquisitions in recent years. Investors may overlook its distribution business, as it may seem less exciting, since it centers on the sale of pharmaceutical and wellness products in overseas markets, with the German-based CC Pharma being a key part of that. But it was the distribution business that generated much of Tilray's growth last year.
The company's net revenue totaled $915.5 million for the fiscal year ending May 31, which was up 11% from the previous year. While it achieved growth across all of its segments, the biggest increase was easily in its distribution business, which remains its largest. Revenue of more than $327 million in that segment grew by 21%, whereas its other business units generated just single-digit growth.
CEO Irwin Simon says the company is poised for further growth and that "Across Europe, we have built one of the industry's most comprehensive medical cannabis and pharmaceutical distribution platforms."
Today's Change
(
4.51
%) $
0.21
Current Price
$
4.75
Is Tilray Brands stock worth buying today? Tilray's stock has been rising in recent days, as the results have led to some increased bullishness. However, it's still down close to 50% since the beginning of the year. The growth is encouraging, but what's disappointing is that its beverage business grew by just under 6%, despite being a key focus for Tilray in recent years.
Plus, this remains an unprofitable business, as Tilray incurred an operating loss of $63 million during the fiscal year. Due to its ongoing challenges, investors may still be better off avoiding the cannabis stock, as it has a lot of work to do before it can prove it's a safe investment to hang on to.
Jefferies potvrdila doporučení Buy pro Tilray a vidí firmu jako diverzifikovaného hráče v oblasti spotřebního zboží, i když snížila cílovou cenu na 19 USD z vyšší předchozí cílové ceny po slabším výhledu zisku. Tržby za čtvrtletí dosáhly 282 milionů USD, nad odhadem 253 milionů USD.
Tilray Inc (NASDAQ:TLRY) is making progress in its transition into a diversified consumer products company, according to Jefferies, which reiterated its ‘Buy’ rating while lowering its price target to $19 from a higher prior target after cutting earnings forecasts.
Shares traded up almost 3% at about $4 on Thursday afternoon
The firm reduced its fiscal 2027 and 2028 EBITDA estimates after management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million, below the consensus estimate of $84 million.
Jefferies now forecasts fiscal 2027 adjusted EBITDA of $75.5 million, down from its previous estimate of $92.1 million.
The analysts noted that Tilray reported quarterly revenue of $282 million, ahead of the consensus estimate of $253 million, supported by growth across beverage alcohol, cannabis, distribution and wellness. They wrote that the results provided "a cleaner look at what the business can look like with BrewDog included," with beverage alcohol becoming a significantly larger contributor to the overall platform.
The firm said the company's transformation over the past year has shifted the investment story beyond cannabis, with Tilray Inc (NASDAQ:TLRY)reasingly becoming a diversified consumer company with multiple growth opportunities.
While lowering its earnings forecasts to reflect a slower profitability ramp, Jefferies said it continues to see upside from BrewDog, the company's Carlsberg partnership and international medical cannabis operations, although integration and investment are expected to weigh on near-term earnings.
Jefferies described the next few months as a period of mixed execution, with improving revenue momentum but a need to demonstrate the ability to scale its beverage business. Over an 18-month horizon, the brokerage maintained a positive outlook, citing improving beer margins, BrewDog's contribution, expanding beverage opportunities through Carlsberg and growth in international medical cannabis.
The firm added that Tilray's balance sheet and brand portfolio position it to benefit from favourable developments in the US cannabis regulatory environment while providing flexibility for future acquisitions.
Tilray Brands, Inc. (TLRY - Free Report) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.2 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -2,050.00%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.24, delivering a surprise of -71.43%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Tilray Brands, which belongs to the Zacks Medical - Products industry, posted revenues of $281.71 million for the quarter ended May 2026, surpassing the Zacks Consensus Estimate by 9.14%. This compares to year-ago revenues of $224.54 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Tilray Brands shares have lost about 55.4% since the beginning of the year versus the S&P 500's gain of 8.3%.
What's Next for Tilray Brands?While Tilray Brands has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Tilray Brands was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.19 on $259.97 million in revenues for the coming quarter and -$0.34 on $1.08 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Phibro Animal Health (PAHC - Free Report) , is yet to report results for the quarter ended June 2026.
This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.72 per share in its upcoming report, which represents a year-over-year change of +26.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Phibro Animal Health's revenues are expected to be $366.14 million, down 3.3% from the year-ago quarter.
Tilray Brands ve 4. čtvrtletí zvýšila tržby na 281,7 milionu USD a upravený EPS byl 0,05 USD oproti očekávané ztrátě 0,01 USD. Tržby z nápojů vyskočily o 61 % na 105,6 milionu USD.
Live Coverage Updates appear automatically as they are published.
Live Updates Pinned 1 hour ago
Live
This live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Tilray’s earnings.
Simply stay on this page, and new updates will appear below automatically. We expect Tilray to release earnings shortly after 4:05 p.m. ET.
28 minutes ago
Live
That wraps up our initial coverage of Tilray’s Q4 results. Thank you for stopping by!
33 minutes ago
Live
Tilray’s Q4 beverage revenue grew 61% year over year to $105.6 million, surpassing cannabis, distribution, and wellness revenue during the quarter.
The BrewDog acquisition created a pro forma global beverage platform approaching $500 million in annual revenue. Tilray said it has already stabilized BrewDog and positioned the business for profitability while gaining access to its global brand, pub network, and hospitality platform.
The next test is margin improvement. Q4 beverage gross margin held steady at 38%, while the full-year figure declined to 36% from 39%. BrewDog is dramatically increasing Tilray’s scale, but management must now prove that scale can produce stronger returns.
34 minutes ago
Live
Tilray Brands finished fiscal 2026 with record revenue of $915.5 million, up 11%, and management expects annual revenue to exceed $1 billion in fiscal 2027.
The company formally guided for adjusted EBITDA of $68 million to $75 million, representing double-digit growth from $61.1 million in fiscal 2026. At the midpoint, adjusted EBITDA would increase approximately 17%.
Tilray is entering the new year with four growing business segments and nearly $235 million in cash, restricted cash, and marketable securities. Delivering the $1 billion milestone alongside higher profitability would strengthen its transformation into a diversified global consumer-products company.
1 hour ago
Live
Tilray Brands just reported Q4 earnings, with shares initially up 4% following the report. Here are the key numbers:
Revenue: $281.7 million vs. $240.8 million expected Adjusted EPS: $0.05 vs. a $0.01 loss expected Adjusted EBITDA: $31.9 million, up 16% year over year Gross Margin: 32%, up 200 basis points Fiscal 2027 Guidance:
Adjusted EBITDA: $68 million to $75 million
Quick Read:
Tilray crushed revenue expectations and unexpectedly turned a profit, while management forecast double-digit adjusted EBITDA growth in fiscal 2027.
Beverage revenue surged 61% to $105.6 million, leading broad growth across all four operating segments and pushing annual revenue toward the $1 billion mark.
1 hour ago
Live
Tilray Brands (NASDAQ:TLRY) reports after the close with shares at $4.03, near the $3.80 52-week low.
The Math on Guidance To hit the reaffirmed $62M-$72M FY26 EBITDA range, Q4 revenue likely lands in the $187M-$197M zone versus $224.54M a year ago. Watch cannabis gross margin, which slid to 27% last quarter.
Positioning and Triggers Options desks lean bullish: full-chain put/call ratio is 0.19. History warns of whipsaws, though. The Q4 FY25 beat still produced a -17.55% earnings-day drop. A clean EBITDA range hit plus an FY27 preview could spark a squeeze; any guidance cut likely retests $3.80.
1 hour ago
Live
What Happened Last Quarter Tilray Brands (NASDAQ:TLRY) Q3 FY26 results showed revenue of $206.73M versus $201.30M consensus, a 2.70% beat, though sales fell 22.96% YoY. Adjusted EPS of $0.02 missed the $0.07 estimate. Adjusted EBITDA rose 19% YoY to $10.71 million.
Management reaffirmed FY2026 adjusted EBITDA guidance of $62M to $72M, flagging Middle East tensions as a supply-chain risk.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Tilray Brands didn't make the cut. Grab the names FREE today.
Shares traded near $6.66 within an hour of release, closed at $6.55 the next day, and drifted to $6.75 a week later.
Key Takeaways: International cannabis revenue climbed 73%, Germany grew 43%, and Project 420 delivered $33 million in annualized savings, while beverage gross margin compressed to 32%. The BrewDog deal and 2027 Carlsberg partnership reset the beverage story.
1 hour ago
Live
With Tilray Brands (NASDAQ:TLRY) set to report Q4 earnings at 4:05 PM ET, here is a clean snapshot of the competing narratives heading into the release.
Bull Case International cannabis hit a company record last quarter with +73% YoY growth to $24.12M, and the distribution segment posted $82.96M (+35% YoY). Technicals are stretched: 14-day RSI sits at 32.82, and the analyst target of $9.05 implies 124.56% upside. Balance sheet supports patience with $204.62M cash and reaffirmed FY26 EBITDA of $62M-$72M. Bear Case Revenue fell 23% YoY in Q3, and Q3 EPS missed by 71.43%. Beverage revenue dropped 21% in Q2 with margins compressing from 40% to 31%. TD Cowen cut its target to $5.00, citing permit delays and fuel surcharges. Composite sentiment reads bearish at 32.58. 2 hours ago
Live
Tilray Brands reports fiscal Q4 earnings after today’s close, with its $62-$72 million adjusted EBITDA target anchoring expectations.
International cannabis revenue climbed 73% year over year last quarter, but beverage sales declined, and gross margin slipped to 27%. Investors will now look for evidence that BrewDog can stabilize the beverage portfolio while international cannabis growth continues and management provides fresh commentary on U.S. rescheduling.
Tilray’s market capitalization has fallen to approximately $497.5 million after shares dropped 55.37% year to date. A clean EBITDA result, beverage stabilization, and early BrewDog traction could reframe Tilray as a scaled global consumer-products platform. Another stumble would reinforce concerns that cannabis growth cannot overcome margin compression, beverage weakness, and cash burn.
Tilray Brands (NASDAQ:TLRY) reports Q4 FY2026 results today at 4:05 PM ET, with the call scheduled for 4:30 PM ET. Shares sit at $4.03, and tonight’s report tests whether CEO Irwin Simon’s global platform lands within its reaffirmed FY2026 EBITDA guide.
The Backdrop: Global Wins, Beverage Drag Q3 FY2026 delivered a $206.73 million revenue beat, but adjusted EPS of $0.02 missed the $0.07 consensus by 71.43%. International cannabis grew 73% to $24.12M, and distribution hit a record $82.96M (+35%).
Beverage revenue declined, and consolidated gross margin slipped from 28% to 27%. TLRY is down 13.15% over the past month and 41.47% over the past year. Management reaffirmed FY2026 adjusted EBITDA of $62M to $72M, flagged Middle East geopolitical risk, and closed the BrewDog acquisition for approximately £40 million in cash.
Consensus Estimates Metric Q4 FY2026 Estimate FY2026 Guide Adjusted EPS -$0.02 Not disclosed Adjusted EBITDA Not disclosed $62M to $72M Sell-side coverage is thin: 3 buys, 7 holds, with a $9.05 average target. TLRY trades at $4.00 per share today, at 0.58x sales and 0.3x book, framing tonight as an EBITDA credibility test more than an EPS event.
What We’re Watching: BrewDog, Margins, and Rescheduling Tonight, I’ll be watching FY2026 adjusted EBITDA. CEO Simon held the $62M-$72M range through three quarters, so any walk-down tonight signals that Q3 execution slippage bled through Q4.
Beverage matters most. Q2 FY2026 revenue fell 21% with gross margin compressing from 40% to 31%. BrewDog closed post-quarter, so I’ll parse integration commentary and any early framing on the 2027 Carlsberg partnership.
International cannabis is another interesting story, with three straight quarters of accelerating growth at +10%, +36%, and +73%. Simon called Q3 the company’s “best quarterly net revenue in Company history.”
Cash is the pressure point. Free cash flow deteriorated to -$24.19M in Q3, and cash sits at $204.62M, down 29.15% YoY. Project 420 delivered $33M in annualized savings, so operating leverage should surface in the SG&A line.
Finally, listen for Simon’s U.S. federal rescheduling framing. He has tied Tilray’s U.S. beverage and medical optionality to that timeline in every recent call.
Earnings History Quarter EPS Surprise Day-of Move 1-Day Move 7-Day Move Q3 FY2026 -71.43% -5.1% +6.68% +9.45% Q2 FY2026 Miss vs $0.00 +0.55% +1.31% +3% Q1 FY2026 In line +22.09% -18.1% -26.67% Q4 FY2025 +200% -17.55% +6.15% +10.21% On average, shares moved -1% seven days after earnings over the past year.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Tilray Brands didn't make the cut. Grab the names FREE today.
TORONTO, July 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, wellness, and beverage industries, today announced the launch of ZONNA, a new cannabis brand introducing fast-acting THC pouches designed for adult consumers seeking a discreet, smoke-free, and convenient cannabis experience.
Launching with Bubble Pink, ZONNA combines innovative Capsoil™ technology with a portable pouch design to deliver a fast-acting experience. Designed to fit comfortably between the gum and lip, the compact pouches offer a discreet and odor-free alternative to traditional cannabis consumption methods.
Blair MacNeil, President, Tilray Canada, stated, "Consumer demand is redefining what cannabis can be, and Tilray is leading that evolution through innovation that expands choice for adult consumers. As preferences move toward products that are discreet, convenient, precise, and smoke-free, ZONNA reflects our ability to anticipate where the category is going and deliver differentiated experiences that meet consumers there. By combining fast-acting Capsoil™ technology with a controlled-dose pouch, we are expanding choice, creating new occasions for cannabis consumption, and reinforcing Tilray’s leadership in bringing forward products that move the industry forward."
Each ZONNA pouch contains 10 mg THC, providing a precise and controlled dose while eliminating much of the uncertainty associated with other consumption formats. The launch format includes 15 pouches per container (150 mg THC per pack) and features a child-resistant puck with separate compartments for unused and used pouches, supporting convenient and responsible disposal.
ZONNA Bubble Pink THC Pouches are now available through licensed cannabis retailers across Canada where cannabis products are sold. Follow ZONNA on Instagram to stay up to date.
Canadian cannabis products are produced and distributed by Aphria Inc., a licensed producer under the Cannabis Act.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Tilray Brands oznámí čtvrtletní výsledky 28. července. Půjde o výsledky za 4. čtvrtletí, které uzavírá fiskální rok 2026. Investoři sledují hlavně další zrychlení růstu tržeb a omezení velké ztráty.
Next week, on July 28, leading cannabis producer Tilray Brands (TLRY 0.58%) is scheduled to report its latest quarterly results. They'll be for its fourth quarter, wrapping up the company's 2026 fiscal year. That's always a big one for companies, as they may make major announcements and also provide guidance for the year ahead.
If the results and news are encouraging, Tilray's stock may soar, leading to a rally in the weeks and months to follow. With the stock trading near its 52-week low, is it a good idea to buy Tilray Brands stock right now, before the company reports its latest results?
Image source: Getty Images.
If Tilray Brands' growth rate continues improving, that could be the catalyst the stock needs Tilray operates in a highly competitive Canadian cannabis market, where it's tough to grow its business while maintaining high margins. As a result, it has leaned heavily on acquisitions and on diversifying into other parts of the world, even into beverages, to grow its sales. The good news is that the company's growth rate has been improving in recent quarters and was back up to double digits in the third quarter.
TLRY Revenue (Quarterly YoY Growth) data by YCharts
If the cannabis company continues to show progress and its growth rate rises further in Q4, that may give investors renewed confidence that the business is going in the right direction. Tilray has struggled to prove it's a good buy, as over the past five years its value has fallen tremendously, by 97%.
However, not only will Tilray need to show good top-line numbers, but its bottom line has been particularly troubling. While acquisitions can boost the top line, they can also add costs and lead to greater losses. In two of the past three fiscal years, Tilray incurred annual losses exceeding $1 billion, as it often incurs non-cash expenses and impairment charges. Avoiding another mammoth loss this fiscal year may be just as important as the company showing strong growth.
Today's Change
(
-0.58
%) $
-0.03
Current Price
$
4.28
Tilray's stock may seem cheap, but it's not a no-brainer buy Unfortunately, Tilray doesn't have a great track record of growing and staying out of the red. It has a lot to prove to growth investors, which is why buying the stock heading into Q4 would be a bit of a gamble. There are still plenty of concerns around the business, and no shortage of uncertainty. That's why a wait-and-see approach still makes the most sense, as despite its losses over the years, it wouldn't be surprising if Tilray's stock continued to decline after earnings.
Tilray Medical zahájila komerční prodej svého prvního léčebného konopí v Panamě. Produkt Tilray Oral Solution CBD100 bude dostupný na lékařský předpis prostřednictvím sítě Farmacias Arrocha.
PANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the commercial launch of its first medical cannabis product in Panama, marking a significant milestone in the company’s ongoing global expansion and commitment to improving patient access to pharmaceutical-grade cannabinoid medicines worldwide.
The launch follows the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP-certified production facilities in Portugal through its joint venture with Solana Life Group S. de R.L. The product is intended to be distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks, where patients will be able to access Tilray Oral Solution CBD 100 under medical prescription. This is expected to provide patients and healthcare professionals with access to regulated, pharmaceutical-quality medical cannabis through established healthcare channels.
The milestone reinforces Tilray Medical’s position as one of the most geographically diversified medical cannabis companies globally. Today, Tilray Medical serves patients across more than 20 countries spanning Europe, Australia, Canada, Latin America, and other emerging international markets, helping advance access to safe, high-quality cannabinoid-based medicines through regulated healthcare systems.
Rajnish Ohri, President, International, Tilray Brands, stated, “At Tilray Medical, we believe every patient deserves access to safe, consistent, pharmaceutical-grade medical cannabis products. Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted healthcare systems around the world. As medical cannabis frameworks continue to advance, we are committed to working alongside healthcare providers, regulators, pharmacists, and patients to help shape the future of responsible access, advance medical education, and deliver high-quality treatment options that improve lives.”
The launch supports Panama’s emerging medical cannabis framework established under Law 242 of 2021 and follows important regulatory advancements by the Ministry of Health, including Resolution No. 0406 of May 12, 2026, which established key requirements for patient access. The Ministry also recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration.
Manufactured in Portugal in accordance with rigorous European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use, where authorized, in patients with qualifying medical conditions authorized under Panamanian legislation. The product reflects Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety, and regulatory compliance.
Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets around the world. The platform enables Tilray Medical to efficiently support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.
The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging medical cannabis region. As governments across the region continue to establish regulatory pathways for cannabinoid-based medicines, Tilray Medical is well-positioned to support healthcare systems with trusted products, scientific expertise, and a proven track record of operating in highly regulated international markets.
As global acceptance of medical cannabis continues to accelerate, Tilray Medical remains focused on advancing patient care, supporting clinical education, investing in research, and expanding access to high-quality medical cannabis products that help address unmet patient needs worldwide.
For further information, please visit: www.Solana.pa
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships, including the Company’s collaboration with Molteni to support the development of the Italian medical cannabis market. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Tilray Brands je stále ztrátová: za devět měsíců do 28. února vzrostly čisté tržby jen o 6 % na 633,7 milionu USD, ale hrubý zisk klesl o 2 % a provozní ztráta činila 46,6 milionu USD.
Tilray Brands (TLRY 1.60%) is a leading cannabis company based in Canada that has been growing its operations all over the world. It's also expanded into beverages in a bid to diversify its operations and pursue even more growth opportunities.
However, while the company has been growing over the years, it remains unprofitable. And many investors bought the cannabis stock in the hopes that it would one day be able to capitalize on opportunities in the U.S. if legalization takes place -- something that hasn't happened yet and may not happen anytime soon.
This year, the marijuana stock is down more than 50%. It's a risky investment, but has its value gotten so low that it's worth buying despite the challenges it's facing?
Image source: Getty Images.
Tilray's business is getting bigger, but whether it's better is debatable Tilray has leaned on acquisitions to grow its business over the years, particularly as it has expanded its alcohol segment, but that isn't necessarily a surefire recipe for success. Acquisitions can be an easy way to generate more revenue, but there's also plenty of work involved to eliminate inefficiencies and unnecessary expenses, so they're accretive to the bottom line.
The company's most recent financial results show that for the nine-month period ending Feb. 28, Tilray's net revenue rose by a fairly modest 6% year over year, totaling $633.7 million. However, despite the increase, its gross profit actually declined by 2% due to worsening margins. And the company incurred an operating loss of $46.6 million. With limited growth and no profitability, it's difficult to make the case that the stock is worth investing in, despite all of its acquisitions.
Today's Change
(
-1.60
%) $
-0.07
Current Price
$
4.31
The stock may look cheap, but that doesn't mean it's a good buy For investors who may be tempted to buy the dip on Tilray's stock, it may be worthwhile to look at the longer, five-year trajectory of the stock. During that longer time frame, the stock has plummeted a massive 97%. Time and time again, investors along the way were likely confident the stock had bottomed out and was destined to rally, only to leave them with significant losses and disappointment.
When a stock has such troubling fundamentals and financials as Tilray, and its growth prospects are questionable, there's no magic price that suddenly makes it worth buying. The business needs to prove to investors that it's worth investing in, and Tilray is nowhere near that point. Simply acquiring more companies doesn't fix its problems. In fact, I'd argue it needs to get leaner and smaller, rather than larger and bloated, just to show growth. While it may look cheap right now, I wouldn't be surprised if it looks even cheaper in the future.
Tilray v červnu klesla téměř o 19 % poté, co vydala nové akcie při swapu dluhu za akcie, snížil se jí cenový cíl a na konci měsíce oznámila akvizici HelloMD.
Tilray Brands (TLRY 1.60%) doesn't, to put it politely, have a history of pleasing its investors. That was well in evidence across June, as the company -- diversifying from its roots as a pure-play marijuana business -- fell into one of its more unattractive habits, announced a new acquisition, and saw an analyst cut his price target on the shares. The combination of these developments pushed Tilray's stock down by nearly 19% that month.
New shares for old notes Over the course of its existence, the chronically loss-making Tilray has often issued new shares in order to bolster its finances. Sure enough, on two separate days in June -- one close to the start of the month, and one at the end -- the company divulged chunky stock flotations. It minted just over 1.2 million new shares in the first, and an additional 2.6 million-plus in the second.
Image source: Getty Images.
What makes the pair something of a departure for Tilray is that they weren't effected to raise capital. Instead, they were the equity side of a debt-for-equity swap the company effected with holders of some of its convertible notes (i.e., debt securities that convert to stock under certain conditions) that pay interest of 5.2%. As notes are booked as debt on the balance sheet, with this financial engineering move Tilray retired roughly $18 million in debt.
That'll improve the balance sheet to a degree (the company had $284 million in long-term borrowings at the end of February) which is, of course, a positive development. What's not so positive is the pile of new shares, as one reason investors have been wary of Tilray is its frequent new share issues. At least the June pair isn't excessively dilutive; the company's outstanding share count topped 123 million.
Later in the month an analyst following Tilray, Bernstein SocGen Group's Nadine Sarwat, cut her price target on the stock. She reduced it quite substantially, to $6.50 per share from $10. She also maintained her rather lukewarm stance on its future, keeping her market perform (hold, in other words) recommendation intact.
On the second-to-last day of the month, Tilray announced its latest acquisition. It is now the owner of HelloMD, a telehealth and patient engagement company focused on medical cannabis.
It didn't disclose the financial terms of the deal, but did say it boosts the company's "direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy."
Today's Change
(
-1.60
%) $
-0.07
Current Price
$
4.31
More losses to come? I think that combination of share price issuance and new asset acquisition is dismaying for some investors. I'd imagine they're wondering why Tilray is effectively reducing its stock's value while opening its wallet for an acquisition.
That wouldn't be such a concern if the company showed signs of reversing its loss-making ways, but I'm not seeing much indication of this yet. Personally, I don't think this stock is a compelling buy right now.
Společnost Tilray Brands kupuje HelloMD, aby posílila přímý přístup k pacientům a vytvořila plně vertikálně integrovaný ekosystém lékařského konopí v Kanadě. Akvizice rozšíří digitální zdravotní platformu a podporu pacientů.
NEW YORK and TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) (“Tilray”), a global leader in medical cannabis, today announced the acquisition of HelloMD Corporation, a digital healthcare and patient engagement platform that expands Tilray’s direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy. Tilray was the successful bidder in HelloMD’s formal sale process and plans to acquire HelloMD’s Canadian medical cannabis assets following formal Court approval on June 29, 2026.
The acquisition will strengthen Tilray’s global medical cannabis platform by expanding direct-to-patient capabilities, enhancing physician and patient education, and deepening engagement across the care journey, while establishing an integrated Canadian framework that connects quality cultivation, clinical expertise, practitioner support, product access, and fulfillment.
As medical cannabis becomes a more established part of healthcare, Tilray is building an integrated care model that supports patients from education and physician consultations to product access, fulfillment, and ongoing support. Historically, medical cannabis has often been considered later in a patient’s care journey. With the appropriate resources and clinical support, HelloMD provides Tilray with a platform to help engage eligible patients earlier through education, practitioner access, and trusted guidance, expanding awareness of regulated, plant-based medical cannabis options as part of a broader approach to natural health and wellness.
HelloMD has supported hundreds of thousands of patients through telehealth consultations, educational resources, and personalized medical cannabis guidance. Its platform complements Tilray’s global healthcare infrastructure, including EU-GMP certified cultivation and manufacturing, pharmaceutical distribution through CC Pharma, medical cannabis clinics, digital pharmacy capabilities, and patient access platforms across North America, Europe, Australia, and other international markets.
Blair MacNeil, President, Tilray Canada, said, “Medical cannabis is becoming a more integrated part of healthcare, and patients are looking for trusted, convenient access to care supported by education and guidance. By combining HelloMD’s digital healthcare platform with Tilray’s medical cannabis portfolio, clinical expertise, and national fulfillment capabilities, we are creating a more connected pathway for patients and healthcare practitioners in Canada. This acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada while strengthening our broader global platform, expanding patient engagement, practitioner support, and access in regulated medical markets. As adoption continues to grow, Tilray is well positioned to serve patients with high-quality medical cannabis solutions and healthcare services across the continuum of care.”
Larry Lisser, CEO, HelloMD, added, “From day one, our mission at HelloMD has been to make medical cannabis more accessible through innovative technology, approachable education, and trusted healthcare experiences. I’m incredibly proud of what our team built alongside our healthcare practitioners and business partners, and of how we scaled together to deliver meaningful outcomes for patients. I believe Tilray has the expertise, infrastructure, and drive to expand the platform’s reach and impact, benefiting patients for years to come.”
The acquisition is expected to enhance Tilray’s ability to deliver a more seamless patient experience, generate insights that support education and engagement, and expand access in regulated medical markets globally.
Tilray also sees an opportunity to broaden patient and consumer awareness in adjacent wellness categories, including sleep support and pain management, where over-the-counter products represent a multi-billion-dollar market in which Tilray is not meaningfully represented today. Subject to applicable regulations, Tilray intends to use HelloMD’s digital education and engagement capabilities to responsibly build awareness of regulated, plant-based medical cannabis alternatives among appropriate audiences seeking natural health solutions.
The acquisition reinforces Tilray’s commitment to advancing medical cannabis through innovation, patient engagement, scientific leadership, expanded global access, and the continued strengthening of HelloMD Corporation’s existing strategic partnerships to ensure continuity of care and sustained value for patients and healthcare practitioners. As Tilray grows its international medical business, the Company remains focused on delivering high-quality medical cannabis products and healthcare solutions to patients worldwide.
Financial terms of the transaction were not disclosed.
About HelloMD
HelloMD Corporation is a leading digital healthcare and patient engagement platform focused on medical cannabis education, physician consultations, and patient support services. Through its technology-driven approach, HelloMD helps patients navigate medical cannabis treatment with confidence and access trusted healthcare resources.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
